Takeda Collaborates With Nanoform For Innovative Plasma Therapy Development

Nanoform Finland, a company focused on enhancing medicine performance, has partnered with Takeda's plasma-derived therapies division to advance formulations aimed at treating rare diseases. After successfully completing in vitro proof of concept studies for a new plasma-derived therapy, Nanoform will supply non-GMP nanomaterial to Takeda for further in vivo testing. Initial results from these studies are anticipated by early 2025.

Edward Haeggstrom, CEO Of Nanoform, said “Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market. We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship.”

The value of this non-GMP pre-clinical project aligns with Nanoform's target range of €0.05m to €0.5m per project. Both Nanoform and Takeda aim to advance these medicine candidates from the clinical stage to market-ready products. Nanoform Biologics employs advanced nanoforming technology that can modify large-molecule drug particles in size and shape while preserving their biological activity. This versatile technology can be used across a wide range of biologics, from 1 to 150KDa, to develop innovative delivery methods, improve drug loading, customize release profiles, and create new drug combinations.